GlaxoSmithKline reported that its Tafinlar (dabrafenib), an orally bioavailable BRAF inhibitorindicated for the treatment of patients with metastatic melanoma, has been approved by NHS England to be routinely funded by the CDF (Cancer Drugs Fund).

Tafinlar is now available for use in metastatic melanoma patients in England who satisfy certain specific criteria.

The usual available doses are 75mg and 150mg and the recommended dose is 150mg orally twice-daily taken at least one hour before or at least two hours after a meal.

Since the efficacy and safety of dabrafenib have not been established in patients with wild-type BRAF melanoma, dabrafenib should not be used in patients with wild-type BRAF melanoma.

The European Commission previously granted marketing approval for dabrafenib as an oral targeted treatment indicated in monotherapy for unresectable melanoma (melanoma that cannot be removed by surgery) or metastatic melanoma (melanoma that has spread to other parts of the body) in adult patients with a BRAF V600 mutation.

Dabrafenib is currently licensed in the EU as monotherapy for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation as detected by a validated test.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The efficacy of dabrafenib in the treatment of adult patients with BRAF V600 mutation positive unresectable or metastatic melanoma has been evaluated in three clinical studies (BRF113683 [BREAK-3], BRF113929 [BREAK-MB], and BRF113710 [BREAK-2]) including patients with BRAF V600E and/or V600K mutations.

Dabrafenib is currently under development for the treatment of solid tumours such as non-small cell lung cancer, colorectal cancer, BRAF mutated thyroid carcinoma and melanoma brain metastases.

Image: Pigmented malignant melanoma. Photo: courtesy of Nephron.